GLP-1 Dose Escalation & Titration Calculator

Why do I have to wait 4 weeks before increasing my GLP-1 dose?

The 4-week minimum between dose escalations is based on two interconnected principles. First, it takes approximately 4–5 weeks of weekly dosing for tirzepatide (t½ = 5 days) or 5–6 weeks for semaglutide (t½ = 7 days) to reach steady-state plasma concentrations — meaning you have not truly experienced your current dose until it has been running for nearly a month. Escalating before steady state means you are increasing the dose before knowing its full effect. Second, GI adaptation to GLP-1 receptor agonism at each dose level takes 3–4 weeks. Escalating faster stacks receptor stimulation on a GI system that has not yet adapted, producing the severe nausea and vomiting that drove ~30% discontinuation rates in early trials that used faster escalation schedules.

Can I skip a step in the tirzepatide or semaglutide titration schedule?

Strongly advised against it. Skipping a dose step means jumping to a plasma concentration that is 2–3× higher than the current adapted level, without the GI adaptation that 4 weeks at the intermediate dose would have provided. In clinical terms: going directly from 2.5 mg to 7.5 mg tirzepatide is pharmacokinetically equivalent to an untreated patient receiving a much higher dose cold. The result, predictably, is severe GI distress.

There are rare, specific scenarios where a prescriber might accelerate escalation under close medical supervision — but these are exceptions managed by physicians, not self-directed shortcuts. If you feel your current dose is "not working," the correct course is to discuss this with your prescriber, not to self-escalate ahead of schedule.

What is a loading dose, and why doesn't 2.5 mg tirzepatide cause weight loss?

A loading dose is a deliberately sub-therapeutic starting dose whose purpose is GI adaptation, not pharmacological effect. Tirzepatide's 2.5 mg and semaglutide's 0.25 mg starting doses produce plasma concentrations far below the receptor occupancy threshold required for meaningful GLP-1-mediated weight loss or glycemic improvement. They work on the same receptors — just not enough of them to drive the downstream metabolic changes that define the drug's therapeutic action.

Think of it as a threshold effect: a small stimulus creates adaptation without triggering the full cascade. This is the same principle behind allergy immunotherapy (microdose injections gradually desensitize immune response) and beta-blocker titration in heart failure (tiny initial doses prevent paradoxical negative effects while the heart adapts).

How long is the full tirzepatide titration schedule to maximum dose?

From the first 2.5 mg injection to the 15 mg maintenance dose is a minimum of 20 weeks following the label protocol (6 steps × ~4 weeks each, with the last step being the maintenance onset). However, the label specifies "at least 4 weeks" at each step — meaning patients who have difficulty tolerating each increase may spend 8, 12, or even 16 weeks at a given dose before advancing. Real-world data shows the median time from initiation to maintenance dose (for patients who reach it) is approximately 6–9 months, not 5 months as the minimum schedule would suggest.

What is the difference between Wegovy and Ozempic semaglutide escalation?

Same molecule (semaglutide), different maximum doses and indications. Wegovy (NDA 215256) is indicated for chronic weight management (BMI ≥30 or ≥27 with comorbidity) and escalates to 2.4 mg/week over 16 weeks: 0.25 → 0.5 → 1 → 1.7 → 2.4 mg. Ozempic (NDA 209637) is indicated for type 2 diabetes management and escalates to a maximum of 2 mg/week: 0.25 → 0.5 → 1 → 2 mg. For Ozempic, the 0.5 mg dose can be a maintenance dose for patients who achieve target glycemic control — whereas for Wegovy, 0.5 mg is always a transitional escalation step toward 2.4 mg.

What should I do if I experience severe nausea during GLP-1 titration?

If nausea is mild to moderate and improving within a week of each injection, this is expected and manageable (see side effect table above). If nausea is severe, persistent, or accompanied by vomiting that prevents adequate nutrition or hydration, contact your prescriber. Per the FDA prescribing information for both tirzepatide and semaglutide: "If a dose increase is not tolerated, consider reverting to the previous dose for an additional period before attempting to increase again."

The step-down is not a failure — it is the correct clinical protocol. Many patients spend 8+ weeks at 2.5 mg or 5 mg tirzepatide before their GI system fully adapts, and then tolerate higher steps more easily. Forcing the escalation schedule while experiencing significant side effects is the fastest route to discontinuation.

What does microdosing mean for GLP-1 therapy?

In the biohacker and longevity community, GLP-1 microdosing typically refers to using doses significantly below the FDA escalation ladder — often 0.5–1 mg tirzepatide weekly or 0.1 mg semaglutide weekly — as a semi-permanent protocol rather than a transitional loading step. The stated goals range from modest metabolic improvement (insulin sensitivity, mild appetite modulation) to simply "priming the system" more gradually than the label escalation allows.

There is no randomized trial data on sub-label GLP-1 dosing for these endpoints. The metabolic benefits of tirzepatide doses below 5 mg (the first therapeutic step) are not established in clinical literature. This does not mean microdosing produces no effect — it means the effect size and clinical relevance are unknown. It is an area of active interest and zero definitive evidence. Individuals pursuing this approach should have a prescriber who is informed and comfortable with off-label dosing.

What happens to my weight if I stop GLP-1 therapy?

Weight regain after GLP-1 discontinuation is well-documented and clinically significant. STEP 4 trial data: participants who switched from semaglutide to placebo after 20 weeks regained 6.9% body weight over 48 weeks, while those who continued treatment lost an additional 7.9% — a 15% difference between continuers and discontinuers. SURMOUNT-4 (tirzepatide): similar pattern. The obesity field now views GLP-1 therapy similarly to antihypertensive medication — a chronic disease management tool that must continue indefinitely to maintain its effect.

This has implications for titration planning: the escalation protocol is not a course of treatment but the beginning of a long-term maintenance strategy. Reaching maintenance dose is not "finishing" the titration — it is the stable plateau from which long-term therapy continues.

Can I take tirzepatide every 10 days instead of every 7 days?

Theoretically, extending the dosing interval has predictable pharmacokinetic effects: a longer interval (10 days vs 7) means a lower trough-to-peak ratio and reduced accumulation at steady state. For tirzepatide with a 5-day half-life, a 10-day interval (instead of 7 days) would result in a lower steady-state Cmax and meaningfully reduced plasma levels at the time of each injection — potentially reducing both side effects and therapeutic efficacy. This is not in the FDA labeling and there are no clinical trials specifically studying extended-interval tirzepatide dosing. Discuss any deviation from the weekly schedule with your prescriber.

What is the retatrutide dosage escalation schedule?

Retatrutide (LY3437943) is a triple agonist targeting GIP, GLP-1, and glucagon receptors — the next-generation after tirzepatide's dual agonism. It is not FDA-approved; the schedule in this calculator is based on the TRIUMPH Phase 3 trial design. The protocol: 2 mg loading dose (weeks 1–4), 4 mg (weeks 5–8), 8 mg (weeks 9–12), 12 mg maintenance (week 13+). Phase 2 data showed approximately 22–24% body weight loss at 12 mg over 48 weeks — the highest weight loss efficacy of any injectable GLP-1-class agent reported to date. Availability is restricted to clinical trial enrollment as of 2025–2026.